These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 36788124)

  • 1. TRYBE®: an Fc-free antibody format with three monovalent targeting arms engineered for long in vivo half-life.
    Davé E; Durrant O; Dhami N; Compson J; Broadbridge J; Archer S; Maroof A; Whale K; Menochet K; Bonnaillie P; Barry E; Wild G; Peerboom C; Bhatta P; Ellis M; Hinchliffe M; Humphreys DP; Heywood SP
    MAbs; 2023; 15(1):2160229. PubMed ID: 36788124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens.
    Moore GL; Bautista C; Pong E; Nguyen DH; Jacinto J; Eivazi A; Muchhal US; Karki S; Chu SY; Lazar GA
    MAbs; 2011; 3(6):546-57. PubMed ID: 22123055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An "Fc-Silenced" IgG1 Format With Extended Half-Life Designed for Improved Stability.
    Borrok MJ; Mody N; Lu X; Kuhn ML; Wu H; Dall'Acqua WF; Tsui P
    J Pharm Sci; 2017 Apr; 106(4):1008-1017. PubMed ID: 28057542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation and Characterization of an IgG4 Monomeric Fc Platform.
    Shan L; Colazet M; Rosenthal KL; Yu XQ; Bee JS; Ferguson A; Damschroder MM; Wu H; Dall'Acqua WF; Tsui P; Oganesyan V
    PLoS One; 2016; 11(8):e0160345. PubMed ID: 27479095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monovalent IgG4 molecules: immunoglobulin Fc mutations that result in a monomeric structure.
    Wilkinson IC; Fowler SB; Machiesky L; Miller K; Hayes DB; Adib M; Her C; Borrok MJ; Tsui P; Burrell M; Corkill DJ; Witt S; Lowe DC; Webster CI
    MAbs; 2013; 5(3):406-17. PubMed ID: 23567207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo pharmacokinetic enhancement of monomeric Fc and monovalent bispecific designs through structural guidance.
    Shan L; Dyk NV; Haskins N; Cook KM; Rosenthal KL; Mazor R; Dragulin-Otto S; Jiang Y; Wu H; Dall'Acqua WF; Borrok MJ; Damschroder MM; Oganesyan V
    Commun Biol; 2021 Sep; 4(1):1048. PubMed ID: 34497355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Full-length recombinant antibodies from
    Rashid MH
    MAbs; 2022; 14(1):2111748. PubMed ID: 36018829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
    Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
    Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments.
    Kenanova V; Olafsen T; Crow DM; Sundaresan G; Subbarayan M; Carter NH; Ikle DN; Yazaki PJ; Chatziioannou AF; Gambhir SS; Williams LE; Shively JE; Colcher D; Raubitschek AA; Wu AM
    Cancer Res; 2005 Jan; 65(2):622-31. PubMed ID: 15695407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Introducing antigen-binding sites in structural loops of immunoglobulin constant domains: Fc fragments with engineered HER2/neu-binding sites and antibody properties.
    Wozniak-Knopp G; Bartl S; Bauer A; Mostageer M; Woisetschläger M; Antes B; Ettl K; Kainer M; Weberhofer G; Wiederkum S; Himmler G; Mudde GC; Rüker F
    Protein Eng Des Sel; 2010 Apr; 23(4):289-97. PubMed ID: 20150180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural characterization of a human Fc fragment engineered for extended serum half-life.
    Oganesyan V; Damschroder MM; Woods RM; Cook KE; Wu H; Dall'acqua WF
    Mol Immunol; 2009 May; 46(8-9):1750-5. PubMed ID: 19250681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fc-Binding Antibody-Recruiting Molecules Targeting Prostate-Specific Membrane Antigen: Defucosylation of Antibody for Efficacy Improvement*.
    Sasaki K; Harada M; Yoshikawa T; Tagawa H; Harada Y; Yonemitsu Y; Ryujin T; Kishimura A; Mori T; Katayama Y
    Chembiochem; 2021 Feb; 22(3):496-500. PubMed ID: 32969164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conformational Plasticity of the Immunoglobulin Fc Domain in Solution.
    Remesh SG; Armstrong AA; Mahan AD; Luo J; Hammel M
    Structure; 2018 Jul; 26(7):1007-1014.e2. PubMed ID: 29731233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycoengineering of EphA4 Fc leads to a unique, long-acting and broad spectrum, Eph receptor therapeutic antagonist.
    Pegg CL; Cooper LT; Zhao J; Gerometta M; Smith FM; Yeh M; Bartlett PF; Gorman JJ; Boyd AW
    Sci Rep; 2017 Jul; 7(1):6519. PubMed ID: 28747680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation and Biological Evaluation of Fc Antigen Binding Fragment-Drug Conjugates as a Novel Antibody-Based Format for Targeted Drug Delivery.
    Jäger S; Wagner TR; Rasche N; Kolmar H; Hecht S; Schröter C
    Bioconjug Chem; 2021 Aug; 32(8):1699-1710. PubMed ID: 34185508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.
    Suzuki T; Ishii-Watabe A; Tada M; Kobayashi T; Kanayasu-Toyoda T; Kawanishi T; Yamaguchi T
    J Immunol; 2010 Feb; 184(4):1968-76. PubMed ID: 20083659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and biodistribution of genetically-engineered antibodies.
    Colcher D; Pavlinkova G; Beresford G; Booth BJ; Choudhury A; Batra SK
    Q J Nucl Med; 1998 Dec; 42(4):225-41. PubMed ID: 9973838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Global conformational changes in IgG-Fc upon mutation of the FcRn-binding site are not associated with altered antibody-dependent effector functions.
    Burvenich IJG; Farrugia W; Liu Z; Makris D; King D; Gloria B; Perani A; Allan LC; Scott AM; Ramsland PA
    Biochem J; 2018 Jul; 475(13):2179-2190. PubMed ID: 29794155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monomeric IgG1 Fc molecules displaying unique Fc receptor interactions that are exploitable to treat inflammation-mediated diseases.
    Ying T; Feng Y; Wang Y; Chen W; Dimitrov DS
    MAbs; 2014; 6(5):1201-10. PubMed ID: 25517305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo neutralization of α-cobratoxin with high-affinity llama single-domain antibodies (VHHs) and a VHH-Fc antibody.
    Richard G; Meyers AJ; McLean MD; Arbabi-Ghahroudi M; MacKenzie R; Hall JC
    PLoS One; 2013; 8(7):e69495. PubMed ID: 23894495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.